当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Eduardo Guimarães Hourneaux De Moura, Bruno Da Costa Martins, Guilherme Sauniti Lopes, Ivan Roberto Bonotto Orso, Suzana Lopes De Oliveira, Marcio C. Mancini, Manoel Passos Galvão Neto, Marco Aurélio Santo, Paulo Sakai and Ivan Cecconello
Background: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device that excludes the duodenum and initial portion of the jejunum from the contact with the chyme. It has been shown to be effective for weight loss and may improve the control of type 2 diabetes mellitus (T2DM). The objective of this study is to evaluate the efficacy of the DJBL in weight loss and in T2DM control over a 24-week period.
Patients and Methods: Obese (BMI ≥ 35 kg/m²) and T2DM patient candidates for bariatric surgery were prospectively assigned to the implant of the DJBL at an academic endoscopy referral center (São Paulo - Brazil) Results: Twenty-two patients were submitted to the implant procedure, with technical success of 100%. At week 24, mean weight loss was 14 kg (p<0.001). BMI dropped on average 5.4 points and excess weight loss was 22.2%. Fasting glucose (baseline = 171.8 mg/dl; W24 = 141.5 mg/dl) and glycosylated hemoglobin levels (8.8% to 7.3%) were significantly reduced. There was also a reduction in the usage of anti-diabetic medications (except metformin).
Conclusions: The DJBL is an effective weight loss method and also promotes glucose control over a 24-week period. Long-term studies with post-removal follow-up are required to determine its role in the management of type 2 diabetes.